© Lisa Berg

GSK expands its board with renowned cancer scientist

British pharma company GlaxoSmithKline plc. is expanding its company board and announced Laurie Glimcher as a non-executive director. Glimcher will join the board on 1 September.

After serving for several years on the board of Bristol-Myers Squibb Co., Laurie Glimcher will soon be a new member of GSK’s company board. She is known to be a scientific and medical cancer expert, and will work as an independent non-executive director in the company. „Laurie brings a wealth of expertise in scientific and medical innovation and public health, which will be invaluable to GSK", states Philip Hampton, Chairman of GSK. Currently, Glimcher is professor of medicine at Harvard Medical School as well as the CEO, president, and an attending physician at the Dana Farber Cancer Institute. She is a member of the Blue Ribbon Panel Advisory Board of the National Cancer Institute and of the American Asthma Foundation. Glimcher has recently been awarded the Kober Medal from the American Association of Physicians for a lifetime of achievements in the field of internal medicine.